Passive Aβ Immunotherapy: Current Achievements and Future Perspectives - PubMed (original) (raw)
Review
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Stephan Schilling et al. Molecules. 2018.
Abstract
Passive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical development are directed against amyloid β (Aβ), the primary amyloid component in extracellular plaques. This review focuses on the current status of Aβ antibodies in clinical development, including their characteristics and challenges that came up in clinical trials with these new biological entities (NBEs). Emphasis is placed on the current view of common side effects observed with passive immunotherapy, so-called amyloid-related imaging abnormalities (ARIAs), and potential ways to overcome this issue. Among these new ideas, a special focus is placed on molecules that are directed against post-translationally modified variants of the Aβ peptide, an emerging approach for development of new antibody molecules.
Keywords: amyloid-β; drug development; monoclonal antibodies; posttranslational modifications.
Conflict of interest statement
I.L. is chief development officer and a stockholder of Probiodrug AG. C.A.L. is an unpaid member on the scientific advisory board of Probiodrug AG.
Figures
Figure 1
Schematic depiction of prominent posttranslational modifications of Aβ. Modifications appearing within the peptide chain and those addressing amino acid side chains (in triangles) are highlighted. APP: amyloid precursor protein; iD: isoaspartate; NO2: nitration pE: pyroglutamate; P: phosphorylation site.
Similar articles
- Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O, Skrabana R, Revajova V, Novak M. Cehlar O, et al. Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037. Bratisl Lek Listy. 2018. PMID: 29663816 Review. - Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ, Liu B, Frost JL, Lemere CA. Fu HJ, et al. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017. CNS Neurol Disord Drug Targets. 2010. PMID: 20205640 Free PMC article. Review. - Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.
Liu J, Yang B, Ke J, Li W, Suen WC. Liu J, et al. Drugs Aging. 2016 Oct;33(10):685-697. doi: 10.1007/s40266-016-0406-x. Drugs Aging. 2016. PMID: 27699633 Review. - The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Sevigny J, et al. Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Nature. 2016. PMID: 27582220 Updated. - A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
Lathuilière A, Laversenne V, Astolfo A, Kopetzki E, Jacobsen H, Stampanoni M, Bohrmann B, Schneider BL, Aebischer P. Lathuilière A, et al. Brain. 2016 May;139(Pt 5):1587-604. doi: 10.1093/brain/aww036. Epub 2016 Mar 8. Brain. 2016. PMID: 26956423
Cited by
- Chlorpromazine-Polypyrrole Drug Delivery System Tailored for Neurological Application.
Krawczyk S, Golba S, Neves C, Tedim J. Krawczyk S, et al. Molecules. 2024 Mar 29;29(7):1531. doi: 10.3390/molecules29071531. Molecules. 2024. PMID: 38611809 Free PMC article. - Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease.
Choi BJ, Park MH, Jin HK, Bae JS. Choi BJ, et al. Exp Mol Med. 2024 Feb;56(2):301-310. doi: 10.1038/s12276-024-01176-4. Epub 2024 Feb 9. Exp Mol Med. 2024. PMID: 38337058 Free PMC article. Review. - Identification of diagnostic molecules and potential traditional Chinese medicine components for Alzheimer's disease by single cell RNA sequencing combined with a systematic framework for network pharmacology.
Wang T, Zhang X, Liu W, Ning F, Hu X, Qin L, Cui M, Yang J, Lv S, Wang Q. Wang T, et al. Front Med (Lausanne). 2024 Jan 5;10:1335512. doi: 10.3389/fmed.2023.1335512. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38249960 Free PMC article. - Neural Stem Cells in the Treatment of Alzheimer's Disease: Current Status, Challenges, and Future Prospects.
Chen X, Jiang S, Wang R, Bao X, Li Y. Chen X, et al. J Alzheimers Dis. 2023;94(s1):S173-S186. doi: 10.3233/JAD-220721. J Alzheimers Dis. 2023. PMID: 36336934 Free PMC article. Review. - Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics.
Jeong H, Shin H, Hong S, Kim Y. Jeong H, et al. Exp Neurobiol. 2022 Apr 30;31(2):65-88. doi: 10.5607/en22004. Exp Neurobiol. 2022. PMID: 35673997 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical